Conduit Pharmaceuticals (CDT) said Friday that it has engaged NJS Foresight Bio-Advisor to identify, source, and support out-licensing deals for in its patent portfolio.
The hiring is meant to expand CDT's commercial reach and speed up potential licensing and royalty deals for its cocrystals and salts, which are meant to improve the solubility, bioavailability and alternative delivery modes of medicines, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.